Key insights
- Johnson & Johnson appointed Ryan Koors as VP of Investor Relations. Recent FDA approvals for Caplyta and Priority Review for IMAAVY, along with the acquisition of Atraverse Medical, signal positive developments for JNJ. These events could lead to a slightly positive short-term impact on the stock.
NEW BRUNSWICK, N.J. - Johnson & Johnson (NYSE:JNJ) appointed Ryan Koors as Vice President of Investor Relations, effective May 7, 2026, according to a press release statement.
Koors will report to Joseph J. Wolk, the company’s Executive Vice President and Chief Financial Officer. He replaces Darren Snellgrove, who is departing to become chief financial officer of Halozyme.
Koors brings more than 20 years of experience at Johnson & Johnson, having worked across multiple divisions including Innovative Medicine, Research & Development, MedTech and Supply Chain. Most recently, he served as Chief Financial Officer and Vice President of Finance for Innovative Medicine Global Research & Development.
His previous roles at the company included Vice President of Finance for MedTech Surgery and Vice President of Finance for Johnson & Johnson MedTech Supply Chain.
Koors joined Johnson & Johnson in 2002. He holds a bachelor’s degree in finance from Wright State University in Ohio and an MBA from Xavier University.
In other recent news, Johnson & Johnson announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for Caplyta, which is used for the prevention of relapse in schizophrenia. Additionally, the FDA has granted Priority Review to Johnson & Johnson’s supplemental Biologics License Application for IMAAVY (nipocalimab-aahu) as a treatment for warm autoimmune hemolytic anemia, marking it as the first therapy to receive such a designation for this condition. This Priority Review status will shorten the FDA’s review timeline to approximately six months. Furthermore, Johnson & Johnson has entered into a definitive agreement to acquire Atraverse Medical, a medical device company specializing in left-heart access and radiofrequency technology. Atraverse Medical’s HOTWIRE Transseptal Access System, which is FDA-cleared, has been utilized in nearly 3,000 clinical procedures. In related developments, new data from a Phase 3 study on IMAAVY in treating generalized myasthenia gravis showed sustained clinical improvements over 120 weeks. These developments highlight Johnson & Johnson’s ongoing efforts in advancing treatments and expanding its medical device capabilities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.